Nomura Asset Management CO LTD Neurocrine Biosciences Inc Transaction History

Nomura Asset Management CO LTD

  • $32.3 Billion
  • Q4 2024

A detailed history of Nomura Asset Management CO LTD transactions in Neurocrine Biosciences Inc stock. As of the latest transaction made, Nomura Asset Management CO LTD holds 53,626 shares of NBIX stock, worth $5.95 Million. This represents 0.02% of its overall portfolio holdings.

Number of Shares
53,626
Previous 56,275 4.71%
Holding current value
$5.95 Million
Previous $6.48 Million 12.98%
% of portfolio
0.02%
Previous 0.02%

Shares

28 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2024

Feb 12, 2025
SELL
$111.62 - $139.44 $295,681 - $369,376
-2,649 Reduced 4.71%
53,626 $7.32 Million
Q3 2024

Nov 15, 2024
SELL
$114.58 - $153.15 $168,776 - $225,589
-1,473 Reduced 2.55%
56,275 $6.48 Million
Q2 2024

Aug 14, 2024
SELL
$130.86 - $143.19 $711,093 - $778,094
-5,434 Reduced 8.6%
57,748 $7.95 Million
Q1 2024

May 13, 2024
SELL
$130.4 - $143.74 $55,159 - $60,802
-423 Reduced 0.67%
63,182 $8.71 Million
Q4 2023

Feb 09, 2024
BUY
$106.07 - $132.76 $10,607 - $13,276
100 Added 0.16%
63,605 $8.38 Million
Q3 2023

Nov 03, 2023
SELL
$94.02 - $117.1 $524,631 - $653,418
-5,580 Reduced 8.08%
63,505 $7.14 Million
Q2 2023

Aug 14, 2023
BUY
$89.53 - $104.87 $8,953 - $10,487
100 Added 0.14%
69,085 $6.51 Million
Q1 2023

Jan 10, 2025
BUY
$94.11 - $123.02 $3.08 Million - $4.03 Million
32,756 Added 90.41%
68,985 $6.98 Million
Q1 2023

May 11, 2023
BUY
$94.11 - $123.02 $3.08 Million - $4.03 Million
32,756 Added 90.41%
68,985 $6.98 Million
Q4 2022

Jan 10, 2025
BUY
$106.72 - $127.06 $234,784 - $279,532
2,200 Added 6.47%
36,229 $4.33 Million
Q4 2022

Feb 14, 2023
BUY
$106.72 - $127.06 $234,784 - $279,532
2,200 Added 6.47%
36,229 $4.33 Million
Q2 2022

Jan 10, 2025
BUY
$75.79 - $100.07 $159,159 - $210,147
2,100 Added 6.58%
34,029 $3.32 Million
Q2 2022

Aug 12, 2022
BUY
$75.79 - $100.07 $159,159 - $210,147
2,100 Added 6.58%
34,029 $3.32 Million
Q1 2022

Jan 10, 2025
SELL
$72.45 - $94.81 $1.76 Million - $2.31 Million
-24,346 Reduced 43.26%
31,929 $2.99 Million
Q4 2021

Jan 10, 2025
BUY
$79.65 - $106.22 $1.08 Million - $1.44 Million
13,529 Added 73.53%
31,929 $2.72 Million
Q4 2021

Feb 01, 2022
BUY
$79.65 - $106.22 $1.08 Million - $1.44 Million
13,529 Added 73.53%
31,929 $2.72 Million
Q3 2021

Jan 10, 2025
SELL
$86.18 - $99.03 $1.14 Million - $1.31 Million
-13,209 Reduced 41.79%
18,400 $1.76 Million
Q3 2021

Nov 12, 2021
SELL
$86.18 - $99.03 $1.14 Million - $1.31 Million
-13,209 Reduced 41.79%
18,400 $1.77 Million
Q2 2021

Jan 10, 2025
BUY
$89.43 - $102.27 $118,673 - $135,712
1,327 Added 4.38%
31,609 $3.08 Million
Q2 2021

Aug 06, 2021
BUY
$89.43 - $102.27 $118,673 - $135,712
1,327 Added 4.38%
31,609 $3.08 Million
Q1 2021

Jan 10, 2025
SELL
$87.57 - $119.4 $2.28 Million - $3.1 Million
-25,993 Reduced 46.19%
30,282 $2.94 Million
Q1 2021

May 14, 2021
SELL
$87.57 - $119.4 $94,750 - $129,190
-1,082 Reduced 3.45%
30,282 $2.95 Million
Q4 2020

Jan 10, 2025
SELL
$86.91 - $108.33 $2.17 Million - $2.7 Million
-24,911 Reduced 44.27%
31,364 $3.01 Million
Q4 2020

Feb 12, 2021
BUY
$86.91 - $108.33 $37,284 - $46,473
429 Added 1.39%
31,364 $3.01 Million
Q2 2020

Aug 13, 2020
BUY
$85.09 - $130.36 $110,957 - $169,989
1,304 Added 4.4%
30,935 $3.78 Million
Q1 2020

May 14, 2020
BUY
$75.11 - $113.76 $105,154 - $159,264
1,400 Added 4.96%
29,631 $2.57 Million
Q4 2019

Feb 13, 2020
BUY
$86.8 - $118.57 $1.18 Million - $1.61 Million
13,620 Added 93.22%
28,231 $3.04 Million
Q2 2017

Aug 14, 2017
BUY
N/A
14,611
14,611 $672,000

Others Institutions Holding NBIX

# of Institutions
655
Shares Held
96.6M
Call Options Held
282K
Put Options Held
281K
View Full List

About NEUROCRINE BIOSCIENCES INC

NBIX Quotes by TradingView
  • Ticker NBIX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 95,639,296
  • Market Cap $10.6B
  • Description
  • Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...
More about NBIX
Track This Portfolio

Track Nomura Asset Management CO LTD Portfolio

Follow Nomura Asset Management CO LTD and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Nomura Asset Management CO LTD, based on Form 13F filings with the SEC.

News

Stay updated on Nomura Asset Management CO LTD with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email